We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Antinuclear Antibody Tests Compared for Systemic Autoimmune Rheumatic Diseases

By LabMedica International staff writers
Posted on 05 Oct 2021
Print article
Image: The Phadia  250 Immunoassay Analyzer: Automated processing of EliA and ImmunoCAP assays (Photo courtesy of Thermo Fisher Scientific).
Image: The Phadia 250 Immunoassay Analyzer: Automated processing of EliA and ImmunoCAP assays (Photo courtesy of Thermo Fisher Scientific).
Systemic autoimmune rheumatic diseases, also known as connective tissue diseases (CTD), including all diseases triggered by the formation of immune complexes that enter the circulation, are then deposited in different tissues and organs, and cause damage.

The diagnosis of systemic autoimmune rheumatic diseases (SARD) is based on the detection of serum antinuclear antibodies (ANA) for which indirect immunofluorescence (IIF) is the golden standard. New solid-phase immunoassays have been developed to be used alone or in combination with the detection of extractable antinuclear antibodies (ENA) to improve SARD diagnosis.

Clinical Biochemists at the Virgen Macarena University Hospital (Seville, Spain) evaluated 323 patients from the primary care, rheumatology, nephrology, and internal medicine services of the hospital. The samples were retrospectively classified: 147 in the SARD group, (including systemic lupus erythematosus, Sjögren's syndrome, mixed connective tissue disease, polymyositis/dermatomyositis, systemic sclerosis, undifferentiated connective tissue diseases, rheumatoid arthritis, and vasculitis); 31 in the Organ-specific autoimmune disease group; 12 in the Malignancies group; and 147 in the non-autoimmune diseases.

Antinuclear antibodies (ANA) screening was performed with the following three techniques: Indirect immunofluorescence (IIF) on HEp-2 cells which allows the detection of antibodies against a wide variety of nuclear molecules and antigens located in the cytoplasm, and RELISA a qualitative indirect enzyme immunoassay (Immunoconcepts, Sacramento, CA, USA); and the EliA CTD Screen was performed using the Phadia 250 instrument (Thermo Fisher Scientific, Waltham, MA, USA). Extractable nuclear antigens (ENA) screening was analyzed using two different methods: LIA Euroline (Euroimmun, Lübeck, Germany); and Thermo Fisher Scientific’s EliA specificities, including SmDP, Rib P, PCNA, U1RNP, Ro, Ro52, Ro60, La, CENP, Scl-70s, Fibrillarin, RNA Pol III, PM-Scl, Jo-1, and Mi-1.

The authors reported the diagnostic accuracy of EliA CTD Screen had a 79% sensitivity and a 91% specificity, and was better than that of ELISA or IIF. The combination of EliA CTD plus IIF had the highest sensitivity (93%). ENA determination revealed that Ro52 and Ro60 were the most prevalent specificities. The use of IIF alone was not able of detecting up to 36% of samples positive for Ro52, and 41% for Ro60.

The authors concluded that the EliA CTD Screen has a better diagnostic performance when compared to IIF and ELISA. The combined use of EliA CTD Screen and IIF clearly improves the rate and accuracy of SARD diagnosis. The use of EliA CTD Screen as first-line screening technique allows the detection of antibodies, which could not be detected by IIF alone. The study was published on August 4, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Virgen Macarena University Hospital
Immunoconcepts
Thermo Fisher Scientific
Euroimmun

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.